Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients
Ravaggi A, Romani C, Pasinetti B, Tassi RA, Bignotti E, Bandiera E, Odicino FE, Ragnoli M, Donzelli C, Falchetti M, Calza S, Santin AD, Pecorelli S. Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. Archives Of Virology 2006, 151: 1899-1916. PMID: 16732494, DOI: 10.1007/s00705-006-0787-y.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, ViralAntibody SpecificityBiomarkersBiotinCancer VaccinesCarcinomaDisease ProgressionDNA-Binding ProteinsEnzyme-Linked Immunosorbent AssayFemaleHumansImmunoglobulin GOncogene Proteins, ViralPapillomavirus E7 ProteinsPapillomavirus VaccinesPrecancerous ConditionsRecombinant ProteinsSensitivity and SpecificityStreptavidinUterine Cervical NeoplasmsVaccinationConceptsCervical cancer patientsCancer patientsHealthy womenHuman papillomavirusE7 oncoproteinsPre-invasive neoplasiaAutologous dendritic cellsSerological immune responsesCervical cancer developmentCapture ELISA methodType of responseHPV 16/18Clinical characteristicsDendritic cellsAntibody levelsAntibody inductionCervical carcinomaSerological evaluationAntibody prevalenceImmune responseAdjunctive toolPatientsCancer developmentELISA methodPotential marker